- IP hearings this week
- IP trials
- IP Judicial review hearings
- IP appeals at the Federal Court of Appeal
(As published on the Federal Court and Federal Court of Appeal websites on Jun 21, 2021 at 00:00:00)
This week in IP
| Date | File No. | Type | Name | Location | Length |
| Jun 21, 2021 | T-1420-18 | CMC | Ncs Multistage Inc. V. Kobold Corporation, Et Al (Patent) | Calgary | 1 h |
| Jun 21, 2021 | T-567-20 | CMC | Ncs Multistage Inc. V. Promac Industries Ltd. (Patent) | Calgary | 1 h |
| Jun 21, 2021 | T-1958-19 | CMC | Louis Vuitton Malletier S.a. Et Al. V. Ruta Melnyk Et Al. (Trade Mark) | Toronto | 30 m |
| Jun 21, 2021 | T-1959-19 | CMC | Christian Dior Couture, S.a. V. Ruta Melnyk Et Al. (Trade Mark) | Toronto | 30 m |
| Jun 22, 2021 | T-1180-20 | JR | Norsteel Building Systems Ltd. V. Toti Holdings Inc. (Trade Mark - JR) | Vancouver | 1 d |
| Jun 23, 2021 | T-550-20 | CMC | 1474031 Ontario Inc. V. 9465693 Canada Inc. (Trade Mark) | Toronto | 30 m |
| Jun 23, 2021 | T-12-20 | JR | H & R Import-export Inc V. Tabesh Global Export Inc Et Al (unknown - JR) | Toronto | 1 d |
| Jun 23, 2021 | T-769-20 | M | Janssen Inc. Et Al. V. Jamp Pharma Corporation (Patent - Macitentan*) | Toronto | 1 d |
| Jun 23, 2021 | T-1606-18 | M | Richards Packaging Inc. V. Distrimedic Inc (Patent) | Montréal | 3 h |
| Jun 24, 2021 | T-1128-20 | MED | Vac Safe Solutions Ltd. V. Jason Hastie Et Al. (Patent) | Edmonton | 1 d |
| Jun 24, 2021 | T-418-20 | CMC | Merck Sharp & Dohme Corp Et Al. V. Sandoz Canada Inc (Patent - Sitagliptin*) | Toronto | 1 h |
| Jun 24, 2021 | T-419-20 | CMC | Merck Sharp & Dohme Corp Et Al. V. Pharmascience Inc. (Patent - Sitagliptin*) | Toronto | 1 h |
| Jun 24, 2021 | T-410-21 | CMC | General Entertainment & Music Inc V. Gold Line Telemanagement Inc Et Al. (Copyright) | Toronto | 30 m |
| Jun 24, 2021 | T-1531-20 | CMC | Boehringer Ingelheim (canada) Ltd Et Al V. Teva Canada Limited (Patent - Linagliptin*) | Toronto | 30 m |
| Jun 24, 2021 | T-1533-20 | CMC | Boehringer Ingelheim (canada) Ltd Et Al V. Teva Canada Limited (Patent - Linagliptin*) | Toronto | 30 m |
| Jun 25, 2021 | T-449-17 | TMC | Farmobile, Llc. V. Farmers Edge Inc. (Patent) | Vancouver | 1 h |
| Jun 25, 2021 | T-555-20 | M | Janssen Inc. Et Al. V. Apotex Inc. (Patent - Apixaban*) | Toronto | 2 h |
| Jun 25, 2021 | T-1910-18 | CMC | Bbc Innovation Corporation V. Bio Bidet Canada Inc. Et Al. (Trade Mark) | Vancouver | 1 h |
Return to top.
Scheduled IP Trials
| Date | File No. | Name | Location | Length |
| Jun 14, 2021 | T-40-18 | Paid Search Engine Tools, Llc V. Google Canada Corporation Et Al (Patent) | Ottawa | 13 d |
| Jul 5, 2021 | T-40-18 | Paid Search Engine Tools, Llc V. Google Canada Corporation Et Al (Patent) | Ottawa | 2 d |
| Jul 19, 2021 | T-1434-14 | Pharmascience Inc. V. Pfizer Canada Ulc (PMNOC - Section 8 - Pregabalin*) | Toronto | 5 d |
| Aug 3, 2021 | T-1434-14 | Pharmascience Inc. V. Pfizer Canada Ulc (PMNOC - Section 8 - Pregabalin*) | Toronto | 4 d |
| Sep 1, 2021 | T-2072-19 | Boehringer Ingelheim (canada) Ltd. Et Al V. Teva Canada Limited (Patent - Aftinib*) | Toronto | 11 d |
| Sep 13, 2021 | T-2072-19 | Boehringer Ingelheim (canada) Ltd. Et Al V. Teva Canada Limited (Patent - Aftinib*) | Ottawa | 1 d |
| Oct 4, 2021 | T-449-17 | Farmobile, Llc. V. Farmers Edge Inc. (Patent) | Vancouver | 16 d |
| Oct 18, 2021 | T-1642-16 | Fluid Energy Group Ltd. V. Mud Master Drilling Fluid Services Ltd. (Patent) | Calgary | 10 d |
| Oct 25, 2021 | T-1606-18 | Richards Packaging Inc. V. Distrimedic Inc (Patent) | Montréal | 15 d |
| Oct 28, 2021 | T-449-17 | Farmobile, Llc. V. Farmers Edge Inc. (Patent) | Vancouver | 2 d |
| Nov 1, 2021 | T-1443-18 | August Image, Llc V. Airg Inc. (Copyright) | Vancouver | 2 d |
| Nov 1, 2021 | T-315-20 | Sunovion Pharmaceuticals Canada Inc. Et Al V. Pharmascience Inc. (Patent - Lurasidone*) | Toronto | 10 d |
| Nov 15, 2021 | T-353-20 | Celgene Inc. Et Al V. Natco Pharma (canada)inc. (Patent - Pomalidomide*) | Toronto | 15 d |
| Nov 15, 2021 | T-815-17 | Pharmascience Inc. V. Meda Ab Et Al (PMNOC - Section 8 - Zolpidem*) | Montréal | 8 d |
| Nov 16, 2021 | T-347-20 | Eisai Limited Et Al V. Taro Pharmaceuticals Inc. (Patent - Perampanel*) | Toronto | 11 d |
| Dec 2, 2021 | T-418-20 | Merck Sharp & Dohme Corp Et Al. V. Sandoz Canada Inc (Patent - Sitagliptin*) | Toronto | 12 d |
| Dec 2, 2021 | T-419-20 | Merck Sharp & Dohme Corp Et Al. V. Pharmascience Inc. (Patent - Sitagliptin*) | Toronto | 12 d |
| Dec 6, 2021 | T-270-20 | Bayer Inc. Et Al V. Pharmascience Inc. (Patent) | Ottawa | 10 d |
| Jan 10, 2022 | T-1420-18 | Ncs Multistage Inc. V. Kobold Corporation, Et Al (Patent) | Calgary | 20 d |
| Jan 10, 2022 | T-567-20 | Ncs Multistage Inc. V. Promac Industries Ltd. (Patent) | Calgary | 20 d |
| Jan 10, 2022 | T-1591-15 | Energizer Brands, Llc Et Al. V. The Gillette Company Et Al (Trade Mark) | Toronto | 10 d |
| Jan 17, 2022 | T-1660-11 | Bernard Charles Sherman Et Al V. Pfizer Canada Inc., Et Al (Patent - Quinapril*) | Toronto | 10 d |
| Jan 24, 2022 | T-549-20 | Janssen Inc. Et Al. V. Sandoz Canada Inc. (Patent - Macitentan*) | Toronto | 7 d |
| Jan 24, 2022 | T-509-21 | Ojo Labs, Inc. Et Al V. Re/max Community Inc (Trade Mark) | Toronto | 5 d |
| Feb 7, 2022 | T-555-20 | Janssen Inc. Et Al. V. Apotex Inc. (Patent - Apixaban*) | Toronto | 5 d |
| Feb 14, 2022 | T-1066-17 | T-rex Property Ab V. Pattison Outdoor Advertising Limited Partnership Et Al (Patent) | Toronto | 15 d |
| Feb 14, 2022 | T-827-20 | Viiv Healthcare Company, Shionogi & Co., Ltd. Et Al. V. Sandoz Canada Inc. (Patent - Dolutegravir*) | Toronto | 10 d |
| Feb 14, 2022 | T-1420-18 | Ncs Multistage Inc. V. Kobold Corporation, Et Al (Patent) | Calgary | 2 d |
| Feb 14, 2022 | T-567-20 | Ncs Multistage Inc. V. Promac Industries Ltd. (Patent) | Calgary | 2 d |
| Feb 14, 2022 | T-1935-13 | Bernard Charles Sherman Et Al V. Pharmascience Inc (Patent - Quinapril*) | Toronto | 10 d |
| Feb 28, 2022 | T-560-20 | Merck Sharp& Dohme Corp Et Al V. Apotex Inc (Patent - Sitagliptin*) | Toronto | 10 d |
| Feb 28, 2022 | T-561-20 | Merck Sharp & Dohme Corp. Et Al V. Apotex Inc. (Patent - Sitagliptin*) | Toronto | 10 d |
| Feb 28, 2022 | T-563-20 | Merck Sharp & Dohme Corp. Et Al V Apotex Inc. (Patent - Sitagliptin*) | Toronto | 10 d |
| Feb 28, 2022 | T-665-20 | Merck Sharp & Dohme Corp Et Al V. Apotex Inc. (Patent - Sitagliptin*) | Toronto | 10 d |
| Feb 28, 2022 | T-666-20 | Merck Sharp & Dohme Corp Et Al V. Apotex Inc. (Patent - Sitagliptin*) | Toronto | 10 d |
| Mar 14, 2022 | T-126-19 | Tekna Plasma Systems Inc. V. Ap&c Advanced Powders & Coatings Inc. (Patent) | Montréal | 24 d |
| Mar 14, 2022 | T-1769-19 | Tekna Plasma Systems Inc. V. Ap&c Advanced Powders & Coatings Inc. (Patent) | Montréal | 24 d |
| Mar 14, 2022 | T-1662-17 | Crocs Canada, Inc. And Crocs Inc. V. Double Diamond Distribution Ltd. (Trade Mark) | Ottawa | 6 d |
| Mar 21, 2022 | T-1861-17 | Denis Cimaf Inc. C. Fecon Inc. (Trade Mark) | Ottawa | 10 d |
| Mar 28, 2022 | T-667-20 | Merck Sharp & Dohme Corp. Et Al V. Jamp Pharma Corporation (Patent - Sitagliptin*) | Toronto | 10 d |
| Mar 28, 2022 | T-798-20 | Opiant Pharmaceuticals Inc. Et Al V. Teva Canada Ltd. (Patent - Naloxone*) | Toronto | 10 d |
| Mar 28, 2022 | T-1187-20 | Merck Sharp & Dohme Corp. Et Al V. Jamp Pharma Corporation (Patent - Sitagliptin*) | Toronto | 10 d |
| Apr 4, 2022 | T-769-20 | Janssen Inc. Et Al. V. Jamp Pharma Corporation (Patent - Macitentan*) | Toronto | 10 d |
| Apr 25, 2022 | T-671-20 | Sunovion Pharmaceuticals Canada Inc. Et Al V. Taro Pharmaceuticals Inc. (Patent - Lurasidone*) | Toronto | 10 d |
| May 30, 2022 | T-2009-19 | Samsung Bioepis Co.,ltd. V. Fresenius Kabi Deutschlandf Gmbh (Patent - Adalimumab*) | Toronto | 10 d |
| May 30, 2022 | T-1581-20 | Celgene Inc. Et Al V. Natco Pharma (canada) Inc. (Patent - Pomalidomide*) | Toronto | 7 d |
| Jun 6, 2022 | T-891-20 | Sunovion Pharmaceuticals Canada Inc. Et Al V. Jamp Pharma Corporation (Patent - Lurasidone*) | Toronto | 10 d |
| Jun 6, 2022 | T-13-20 | Andritz Ltd Et Al. V. Cortex North America Corporation (Patent) | Montréal | 12 d |
| Jun 13, 2022 | T-952-20 | Google Llc V. Sonos, Inc. (Patent) | Toronto | 10 d |
| Jul 4, 2022 | T-601-20 | Merck Sharp & Dohme Corp Et Al. V. Apotex Inc. (Patent - Sitagliptin*) | Toronto | 12 d |
| Jul 4, 2022 | T-602-20 | Merck Sharp & Dohme Corp. Et Al. V. Apotex Inc. (Patent - Sitagliptin*) | Toronto | 12 d |
| Jul 4, 2022 | T-668-20 | Merck Sharp & Dohme Corp. Et Al V. Jamp Pharma Corporation (Patent - Sitagliptin*) | Toronto | 12 d |
| Jul 4, 2022 | T-670-20 | Merck Sharp & Dohme Corp, Et Al V. Sandoz Canada Inc. (Patent - Sitagliptin*) | Toronto | 12 d |
| Jul 4, 2022 | T-5-21 | Merck Sharp & Dohme Corp. Et Al V. Sandoz Canada Inc. (Patent - Sitagliptin*) | Toronto | 12 d |
| Jul 4, 2022 | T-414-21 | Merck Sharp & Dohme Corp. Et Al V. Sandoz Canada Inc. (Patent) | Toronto | 12 d |
| Jul 4, 2022 | T-673-20 | Merck Sharp & Dohme Corp. Et Al V. Pharmascience Inc. (Patent - Sitagliptin*) | Toronto | 12 d |
| Jul 4, 2022 | T-1441-20 | Janssen Inc. Et Al V. Pharmascience Inc. (Patent - Paliperidone*) | Toronto | 10 d |
| Jul 5, 2022 | T-1207-20 | Pfizer Canada Ulc Et Al. V. Jamp Pharma Corporation (Patent - Tofacitinib*) | Toronto | 9 d |
| Aug 2, 2022 | T-1268-20 | Janssen Inc. Et Al. V. Sandoz Canada Inc (Patent - Canagliflozin*) | Toronto | 10 d |
| Aug 15, 2022 | T-1467-20 | Celgene Inc. Et Al V. Taro Pharmaceuticals Inc. (Patent - Lenalidomide*) | Toronto | 15 d |
| Sep 6, 2022 | T-251-21 | Merck Sharp & Dohme Corp. Et Al V. Dr. Reddy's Laboratories Ltd. (Patent - Sitagliptin*) | Toronto | 12 d |
| Sep 6, 2022 | T-252-21 | Merck Sharp & Dohme Corp. Et Al V. Dr. Reddy's Laboratories Ltd. (Patent - Sitagliptin*) | Toronto | 12 d |
| Sep 6, 2022 | T-190-21 | Merck Sharp & Dohme Corp.et Al V. Teva Canada Limited (Patent - Sitagliptin*) | Toronto | 12 d |
| Sep 6, 2022 | T-253-21 | Merck Sharp & Dohme Corp. Et Al V. Teva Canada Limited (Patent - Sitagliptin*) | Toronto | 12 d |
| Sep 12, 2022 | T-16-21 | Boehringer Ingelheim (canada)ltd. Et Al V. Sandoz Canada Inc. (Patent - Linagliptin*) | Toronto | 15 d |
| Sep 26, 2022 | T-124-21 | Janssen Inc. Et Al V. Apotex Inc. (Patent - Paliperidone*) | Toronto | 10 d |
| Sep 29, 2022 | T-190-21 | Merck Sharp & Dohme Corp.et Al V. Teva Canada Limited (Patent - Sitagliptin*) | Toronto | 2 d |
| Sep 29, 2022 | T-251-21 | Merck Sharp & Dohme Corp. Et Al V. Dr. Reddy's Laboratories Ltd. (Patent - Sitagliptin*) | Toronto | 2 d |
| Sep 29, 2022 | T-252-21 | Merck Sharp & Dohme Corp. Et Al V. Dr. Reddy's Laboratories Ltd. (Patent - Sitagliptin*) | Toronto | 2 d |
| Sep 29, 2022 | T-253-21 | Merck Sharp & Dohme Corp. Et Al V. Teva Canada Limited (Patent - Sitagliptin*) | Toronto | 2 d |
| Oct 17, 2022 | T-592-21 | Astrazeneca Canada Inc. Et Al V. Teva Canada Limited (Patent - Dapagliflozin*) | Toronto | 10 d |
| Oct 17, 2022 | T-6-21 | Merck Sharp & Dohme Corp. Et Al V. Sandoz Canada Inc. (Patent - Sitagliptin*) | Toronto | 7 d |
| Oct 17, 2022 | T-415-21 | Merck Sharp & Dohme Corp. Et Al V. Sandoz Canada Inc. (Copyright - Sitagliptin*) | Toronto | 7 d |
| Oct 31, 2022 | T-383-21 | Astrazeneca Canada Inc. Et Al V. Sandoz Canada Inc. (Patent - Dapagliflozin*) | Toronto | 9 d |
| Nov 14, 2022 | T-557-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Ottawa | 20 d |
| Nov 14, 2022 | T-559-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - ADALIMUMAB*) | Ottawa | 20 d |
| Nov 14, 2022 | T-560-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Ottawa | 20 d |
| Nov 14, 2022 | T-561-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - ADALIMUMAB*) | Ottawa | 20 d |
| Nov 14, 2022 | T-572-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - ADALIMUMAB*) | Ottawa | 20 d |
| Nov 14, 2022 | T-573-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Ottawa | 20 d |
| Nov 14, 2022 | T-577-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - ADALIMUMAB*) | Ottawa | 20 d |
| Nov 14, 2022 | T-581-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Ottawa | 20 d |
| Nov 14, 2022 | T-380-21 | Biomarin Pharmaceutical Inc. V. Dr. Reddy's Laboratories Ltd. (Patent - Sapropterin*) | Toronto | 10 d |
| Nov 14, 2022 | T-1531-20 | Boehringer Ingelheim (canada) Ltd Et Al V. Teva Canada Limited (Patent - Linagliptin*) | Toronto | 15 d |
| Nov 14, 2022 | T-1533-20 | Boehringer Ingelheim (canada) Ltd Et Al V. Teva Canada Limited (Patent - Linagliptin*) | Toronto | 15 d |
| Dec 5, 2022 | T-668-21 | Lundbeck Canada Inc. Et Al. V. Apotex Inc. Et Al. (Patent) | Toronto | 10 d |
| Dec 5, 2022 | T-373-21 | Bristol-myers Squibb Canada Co Et Al V. Sun Pharma Canada Inc. (Patent - Apixaban*) | Toronto | 10 d |
| Dec 13, 2022 | T-592-21 | Astrazeneca Canada Inc. Et Al V. Teva Canada Limited (Patent - Dapagliflozin*) | Toronto | 1 d |
| Dec 15, 2022 | T-383-21 | Astrazeneca Canada Inc. Et Al V. Sandoz Canada Inc. (Patent - Dapagliflozin*) | Toronto | 1 d |
| Dec 19, 2022 | T-557-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Toronto | 3 d |
| Dec 19, 2022 | T-559-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - ADALIMUMAB*) | Toronto | 3 d |
| Dec 19, 2022 | T-560-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Toronto | 3 d |
| Dec 19, 2022 | T-561-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - ADALIMUMAB*) | Toronto | 3 d |
| Dec 19, 2022 | T-572-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - ADALIMUMAB*) | Toronto | 3 d |
| Dec 19, 2022 | T-573-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Toronto | 3 d |
| Dec 19, 2022 | T-577-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - ADALIMUMAB*) | Toronto | 3 d |
| Dec 19, 2022 | T-581-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Toronto | 3 d |
| Jan 9, 2023 | T-1007-20 | Medexus Pharmaceuticals Inc. Et Al. V. Accord Healthcare Inc. (Patent) | Ottawa | 14 d |
| Jan 16, 2023 | T-188-21 | Merck Sharp & Dohme Corp. Et Al V. Teva Canada Limited (Patent - Sitagliptin*) | Toronto | 10 d |
| Jan 16, 2023 | T-249-21 | Merck Sharp & Dohme Corp. Et Al V. Dr. Reddy's Laboratories Ltd. (Patent - Sitagliptin*) | Toronto | 10 d |
| Jan 16, 2023 | T-250-21 | Merck Sharp & Dohme Corp. Et Al V. Dr. Reddy's Laboratories Ltd. (Patent - Sitagliptin*) | Toronto | 10 d |
| Jan 16, 2023 | T-254-21 | Merck Sharp & Dohme Corp. Et Al V. Teva Canada Limited (Patent - Sitagliptin*) | Toronto | 10 d |
| Jan 30, 2023 | T-588-21 | Celgene Inc And Celgene Corporation V. Apotex Inc (Patent - Pomalidomide*) | Toronto | 10 d |
| Jan 30, 2023 | T-589-21 | Celgene Inc And Celgene Corporation V. Apotex Inc (Patent - Pomalidomide*) | Toronto | 10 d |
| Jan 30, 2023 | T-590-21 | Celgene Inc And Celegene Corporation V. Apotex Inc. (Patent - Pomalidomide*) | Toronto | 10 d |
| Jan 30, 2023 | T-591-21 | Celgene Inc And Celgene Corporation V. Apotex Inc (Patent - Pomalidomide*) | Toronto | 10 d |
| Feb 27, 2023 | T-788-21 | Boehringer Ingelheim (canada) Ltd. Et Al V. Jamp Pharma Corporation (Patent) | Toronto | 15 d |
| Jun 19, 2023 | T-607-21 | Apotex Inc. V. Janssen Inc. Et Al. (Patent) | Toronto | 10 d |
Return to top.
Scheduled Judicial Review Hearings
| Date | File No. | Name | Type | Location | Length |
| Jun 22, 2021 | T-1180-20 | Norsteel Building Systems Ltd. V. Toti Holdings Inc. | Trade Mark Expungement | Vancouver | 1 d |
| Jun 23, 2021 | T-12-20 | H & R Import-export Inc V. Tabesh Global Export Inc Et Al | S. 18.1 Application for Judicial Review | Toronto | 1 d |
| Jun 29, 2021 | T-1409-20 | Yiwu Thousand Shores E-commerce Co. Ltd V. Jinxing Lin | Trade Mark Infringement | Toronto | 1 d |
| Jul 20, 2021 | T-451-21 | Rick Spagnuolo Et Al V. Re/max Hallmark Realty Ltd | Trade Mark - Appeal of a decision of the Registrar | Toronto | 2 h |
| Sep 30, 2021 | T-617-20 | Novo Nordisk Canada Inc. V. Minister Of Health Et Al. | Access to Information | Toronto | 3 h |
Return to top.
Scheduled IP Appeals
| Date | File No. | Name | Type | Location | Length |
* Medicinal ingredients are based on automated analysis and should not be relied upon.
Return to top.